Skip to content
Adam Torkildson – Lifestyle
Author:
Spur Therapeutics
Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1
July 7, 2026
Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1
May 4, 2026
Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium
April 21, 2026